Liquid biopsy tests involve the sampling and analysis of blood or other body fluids for detecting and monitoring cancer. They offer minimally invasive alternatives to tissue biopsies for detecting various cancers. Advancements in liquid biopsy technologies have enabled the detection of minimal residual disease and monitoring of treatment responses. Next generation sequencing and digital PCR techniques are being applied to analyze cell-free DNA or circulating tumor cells in blood samples. This has significantly improved the sensitivity and accuracy of liquid biopsy tests.

The global Liquid Biopsy Market is estimated to be valued at US$ 5.25 Bn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The technological advancement in liquid biopsy tests has accelerated their adoption over tissue biopsies. Next generation sequencing enables comprehensive molecular profiling using very small samples. This allows repeated tests during cancer treatment for real-time monitoring. Digital PCR technology provides highly sensitive detection of rare cancer biomarkers. These technological upgrades have expanded the clinical applications of liquid biopsies from treatment monitoring to early disease detection. The improvement in analytics is expected to boost the liquid biopsy market during the forecast period.

Segment Analysis
The liquid biopsy market is dominated by the circulating tumor cell (CTC) detection segment owing to its ability to provide comprehensive profiling data of tumors for developing targeted therapies. CTC detection analyzes various tumor-specific biomarkers on circulating tumor cells that have escaped from the primary tumor site to other areas of the body. The growing popularity of minimally invasive procedures is expected to boost the adoption of CTC-based liquid biopsy tests for diagnosis and treatment monitoring.

Key Takeaways
The global liquid biopsy market growth is expected to witness high growth over the forecast period driven by rising cancer incidence and growing preference for non-invasive procedures. The global Liquid Biopsy Market is estimated to be valued at US$ 5.25 Bn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030.

Regional analysis
North America currently dominates the global liquid biopsy market and is expected to maintain its leading position during the forecast period. This can be attributed to the widespread availability of advanced diagnostic technologies, rising healthcare spending, and growing awareness levels about liquid biopsy. Asia Pacific is slated to be the fastest-growing regional market owing to improving healthcare infrastructure, increasing research funding for cancer diagnosis, and rising medical tourism in countries such as India, China and Japan.

Key players
Key players operating in the liquid biopsy market are BASF SE, Spectrum Chemical Manufacturing Corp., Kudos Chemie Limited, AVT Natural Products, Tianjin Zhongman Pharmaceutical Company Ltd., Shandong Xinhua Pharma, Aarti Industries Limited, Bakul Group, Taj Pharmaceuticals Limited., and Jilin Shulan Synthetic Pharmaceutical Co. Ltd. BASF has a wide geographic presence with robust R&D capabilities and extensive experience in developing drugs and diagnostic products. Spectrum Chemical is a leading producer of pharmaceutical intermediates and active ingredients with a focus on the oncology segment.

Get more insights on this topic: https://www.newswirestats.com/liquid-biopsy-market-industry-insights-trends-liquid-biopsy-market/

Explore more information on this topic, Please visit: https://allmeaninginhindi.com/navigating-the-evolving-landscape-of-enterprise-artificial-intelligence-solutions/